SCHEMBL22926083

SCHEMBL22926083

Nc1ncn(-c2ccc(C(F)(F)F)cn2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
ABL1 P00519 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
ALDH1A1 P00352 2/20 0.40
APAF1 O14727 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HDAC4 P56524 1/20 0.39
CYP3A4 P08684 2/20 0.39
MAOB P27338 1/20 0.39
HSD11B1 P28845 1/20 0.38
HPGD P15428 1/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620927 1.00 KDM4E (0.42) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL31348082 0.81 MAPT (0.47) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL22897587 0.81 MAPT (0.40) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL29559857 0.80 KIF11 (0.44) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL18284894 0.78 DHFR (0.42) TDP1
SCHEMBL18579433 0.77 KDM4E (0.39) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL31013386 0.77 NOTUM (0.43) TDP1
SCHEMBL28733791 0.75 KMT2A (0.43) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL22897578 0.75 KMT2A (0.36) KDM4EABL1LMNAMAPTSMN1; SMN2
SCHEMBL29560015 0.75 KMT2A (0.36) KDM4EABL1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB KDM4E 1551/4885ABL1 1897/4885LMNA 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.